---
document_datetime: 2023-09-21 19:12:21
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/optimark-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: optimark-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.3801807
conversion_datetime: 2025-12-22 10:38:08.783014
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Optimark

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                      | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------------------------------------|---------------------------------------------|------------------------------------------------|----------------------------------|-----------------------------------|
| T/0037               | Transfer of Marketing Authorisation                                                        | 14/03/2017                                  | 11/04/2017                                     | SmPC, Labelling and PL           |                                   |
| PSUSA/1508/ 201601   | Periodic Safety Update EU Single assessment - gadoversetamide Medicinal                    | 02/09/2016                                  | n/a                                            |                                  | PRAC Recommendation - maintenance |
| IB/0036              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing | 20/07/2016                                  | 16/02/2017                                     | Annex II                         |                                   |

<!-- image -->

Medicinal product no longer authorised

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet).

The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                              |                    |               |                       |                                                                                                                                                                                                                                                                                           |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0031            | Update of section 4.4 of the SmPC in order to add a warning on acute kidney injury based on information derived from post-marketing reports. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce some editorial changes and to bring the PI in line with the latest QRD template version 9.1. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 10/03/2016         | 16/02/2017    | SmPC, Annex II and PL | In patients with baseline renal impairment, acute kidney injury requiring dialysis has occurred with the use of Optimark. The risk of acute kidney injury may increase with an increased dose of the contrast agent. Administer the lowest dose possible for adequate imaging. authorised |
| IAIN/0033          | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                 | 08/12/2015         | n/a no longer |                       |                                                                                                                                                                                                                                                                                           |
| PSUSA/1508/ 201501 | Periodic Safety Update EU Single assessment - gadoversetamide                                                                                                                                                                                                                                                                                                                                                                                                                                   | 24/09/2015 product | 19/11/2015    | SmPC                  | Please refer to Optimark PSUSA/00001508/201501 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation                                                                                                                            |
| IB/0030            | B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue Medicinal                                                                                                                                                                                                                                 | 22/10/2015         | n/a           |                       |                                                                                                                                                                                                                                                                                           |
| IA/0029/G          | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                              | 24/06/2015         | n/a           |                       |                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                 |                    |                      |             |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------|-------------|
| IB/0027   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                              | 21/04/2015         | 02/06/2015           | SmPC and PL |
| IB/0026   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                | 30/03/2015         | n/a                  | authorised  |
| IB/0025   | To postponing the due date for the submission of the final study report evaluating the potential for long- term retention of gadolinium in bone (bone study) from September 2014 to June 2016 C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 15/12/2014 product | 02/06/2015 no longer | Annex II    |
| IA/0024   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) Medicinal                                                                                                                                  | 27/10/2014         | n/a                  |             |
| IB/0023/G | This was an application for a group of variations. B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)                                                                                                                                                           | 08/10/2014         | n/a                  |             |

<div style=\"page-break-after: always\"></div>

|           | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                         |                    |                   |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0021   | Update of section 6.6 of the Summary of Product Characteristics (SmPC) on the implementation of traceability measures in context with Electronic Health Records and corresponding updates to Package Leaflet (PL) and Labelling as requested per PRAC and CHMP. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 25/09/2014         | 01/12/2014 longer | SmPC, Labelling and PL | As per PRAC/CHMP request, the MAH adapted the traceability measures in light of the increasing use of Electronic Health Records by Healthcare Professionals and Institutions in the Product Information (PI). The PI has been updated to include the following information: - SmPC, Package Leaflet: If electronic patient records are used, the name of the product, the batch number and the dose should be entered into the patient record. - Labelling (intermediate and outer packaging): For recording: stuck the peel-off tracking label onto the patient record; for electronic records: enter product name, batch no and dose. - Labelling (inner packaging): This sticky label should be stuck on patient records. For electronic records: enter product name, batch no. and dose. authorised |
| PSUV/0022 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                         | 11/09/2014 product | n/a no            |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IAIN/0020 | C.I.12 - Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to additional monitoring Medicinal                                                                                                                                                                         | 13/02/2014         | 01/12/2014        | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0019   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                  | 13/12/2013         | 01/12/2014        | Annex II               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IAIN/0018 | B.II.b.1.a - Replacement or addition of a                                                                                                                                                                                                                                                                                                                      | 23/09/2013         | n/a               |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | manufacturing site for the FP - Secondary packaging site                                                     |                              |               |                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|--------------------------------------------------------------------------------------------------------------|------------------------------|---------------|-----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0017 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation               | 29/07/2013                   | n/a           |                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IB/0016   | B.II.b.3.z - Change in the manufacturing process of the finished product - Other variation                   | 05/07/2013                   | n/a           |                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| T/0015    | Transfer of Marketing Authorisation                                                                          | 15/02/2013                   | 13/03/2013    | SmPC, Labelling and PL authorised | Transfer of MA from Covidien Deutchland GmbH to Mallinckrodt Deutchland GmbH.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0014   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 12/09/2012                   | n/a longer    |                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| R/0012    | Renewal of the marketing authorisation.                                                                      | 19/04/2012 Medicinal product | 15/06/2012 no | SmPC, Annex II, Labelling and PL  | Based upon the data that have become available since the granting of the initial Marketing Authorisation, the CHMP considers that the benefit-risk balance of Optimark remains positive, but considers that its safety profile is to be closely monitored for the following reasons: â€¢ Optimark is a linear non-ionic chelates gadolinium contrast agent, classified among the High Risk category for Nephrogenic Systemic Fibrosis (NSF). Two further annual cumulative reviews on NSF cases are to be submitted; in addition a study to investigate the long-term gadolinium retention in human bone is to be performed. NSF is a serious safety issue and the results of this further awaited data could have an impact on the benefit-risk balance of the product. The CHMP decided that the MAH should continue to submit yearly PSURs. |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                    |                      |                                  | Therefore, based upon the safety profile of Optimark, which requires the submission of yearly PSURs, the CHMP concluded that the MAH should submit one additional renewal application in 5 years time.                                                                                                                                                                                                                                                                          |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0013   | to replace the currently used resin for the manufacturing of the syringe barrels with a new resin material. B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products                                                                                                                                                                                                            | 24/05/2012         | 24/05/2012           | authorised                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0010   | Update of section 4.8 of the SmPC further to a review of the safety database conducted by the MAH and in order to also bring the SmPC in line with the SmPC guideline. The Package leaflet has been updated accordingly. The MAH also took the opporuntiy to update the product information in line with the QRD template (version 8, revision 1). C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data Medicinal | 15/03/2012 product | 20/04/2012 no longer | SmPC, Annex II, Labelling and PL | Further to a review of the MAH's safety database conducted by the MAH and also in line with the SmPC guideline, changes were made to the 'Undesirable effects' section of the Summary of Product Characteristics (SmPC). Overall, the frequency of several adverse reactions was revised and the adverse reactions 'conjunctivitis', 'vertigo', 'laryngeal oedema', 'chills' and 'albumin in urine' were added to the SmPC. The Package Leaflet has been revised in accordance. |
| IA/0011/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or                                                                                                                                                                                                                                                                                                  | 17/10/2011         | n/a                  |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                    |               |                     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|---------------------|
| IA/0009/G | This was an application for a group of variations. C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the | 30/09/2011         | n/a no longer | Annex II authorised |
| IB/0007/G | QPPV This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.3.b - Change in batch size (including batch size Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/02/2011 product | n/a           |                     |

<div style=\"page-break-after: always\"></div>

| IA/0006   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                        | 12/11/2010         | n/a           |                                  |                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A20/0004  | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 19 November 2008, the opinion of Committee for Medicinal Products for Human Use (CHMP) on measures necessary to ensure the safe and effective use of Optimark and on whether the marketing authorisation should be varied in relation to its use in special patient's population more at risk to develop nephrogenic systemic fibrosis (NSF). | 19/11/2009         | 10/05/2010    | SmPC, Annex II and PL            | Please refer to the assessment report published after deletion of commercially confidential information: EMEA/H/C/0745/A20/0004. authorised                                                                                                                                                                                                                                                     |
| IA/0005   | IA_13_a_Change in test proc. for active substance - minor change                                                                                                                                                                                                                                                                                                                                                                          | 10/11/2009         | n/a longer    |                                  |                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0003   | Update of DDPS (Pharmacovigilance)                                                                                                                                                                                                                                                                                                                                                                                                        | 19/03/2009 product | 03/04/2009 no | Annex II                         | Update the Detailed Description of the Pharmacovigilance System (DDPS) as consequence of corrective and preventive actions following a pharmacovigilance inspection and to be in compliance with Volume 9A of the Rules Governing Medicinal Products in the European Union. Consequently, Annex II of the product information was updated with the agreed version number of the DDPS (2009/02). |
| IA/0002   | IA_01_Change in the name and/or address of the marketing authorisation holder Medicinal                                                                                                                                                                                                                                                                                                                                                   | 29/04/2008         | n/a           | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0001   | Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                           | 21/02/2008         | 27/03/2008    | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                 |